ReviewRheumatology (Oxford, England)2020
Predicting treatment response to IL6R blockers in rheumatoid arthritis.
Review in Rheumatology (Oxford, England), 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 14 papers, 3 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
14 citing papers in PubMed, 3 syntheses or guidelines pooled it.
- Mendelian randomization identifies multiple immune cell surface markers as potential causal contributors and drug targets in rheumatoid arthritis.The Journal of international medical research · 2026Pooled it
- Pooled it
- Natural and iatrogenic ocular manifestations of rheumatoid arthritis: a systematic review.International ophthalmology · 2022Pooled it
- Clinical and molecular data to predict flares in DMARD optimization in rheumatoid arthritis: a randomized, controlled, open-label, non-inferiority trial.Rheumatology (Oxford, England) · 2026Trial
- Deep molecular profiling of synovial biopsies in the STRAP trial identifies signatures predictive of treatment response to biologic therapies in rheumatoid arthritis.Nature communications · 2025Trial
- Biomarkers of treatment response in rheumatoid arthritis: from conventional markers to tissue immunophenotype.Frontiers in immunology · 2026Review
- MAPK4 inhibits the early aberrant activation of B cells in rheumatoid arthritis by promoting the IRF4-SHIP1 signaling pathway.Cell death & disease · 2025Article
- Interlinking pathways: a narrative review on the role of IL-6 in cancer and atherosclerosis.Cardiovascular diagnosis and therapy · 2024Review
- Predicting Disease Activity in Rheumatoid Arthritis With the Fibromyalgia Survey Questionnaire: Does the Severity of Fibromyalgia Symptoms Matter?The Journal of rheumatology · 2023Article
- Differential absolute plasma IL-6 concentrations between two immunoassay platforms in intensive care unit patients with COVID-19.Biomarkers in medicine · 2023Article
- Neutrophil count reduction 1 month after initiating tocilizumab can predict clinical remission within 1 year in rheumatoid arthritis patients.Rheumatology international · 2022Article
- The REMDACTA trial: do interleukin receptor antagonists provide additional benefit in COVID-19?Intensive care medicine · 2021Article
- Rheumatology in the era of precision medicine: synovial tissue molecular patterns and treatment response in rheumatoid arthritis.Current opinion in rheumatology · 2021Review
- Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Patients with severe, active RA who have not responded to conventional therapy may receive biological disease modifying anti-rheumatic drugs (bDMARDs). However, 40% of cases do not achieve complete disease control, resulting in a negative impact on patient quality of life and representing a waste of healthcare resources. Ongoing research seeks to establish biomarkers, which can be used to predict treatment response to biologics in RA to enable more targeted approaches to treatment. However, much of the work has focused on one class of biologic drug, the TNF inhibitors (TNFi). Here, we will review the current state of research to identify biomarkers predictive of response to the class of bDMARDs targeting the IL6R. While success has been limited thus far, serum drug and low ICAM1 levels have shown promise, with associations reported in independent studies. The challenges faced by researchers and lessons learned from studies of TNFi will be discussed.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.